Neurocrine Biosciences, Inc.
Price Action
Technical Summary
CONSOLIDATINGNeurocrine Biosciences, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 41), showing significant lag compared to the market leaders. Earnings growth of 23% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $131.44 | +11.86% | ABOVE |
| 50 SMA | $130.82 | +12.39% | ABOVE |
| 100 SMA | $134.35 | +9.43% | ABOVE |
| 150 SMA | $137.70 | +6.77% | ABOVE |
| 200 SMA | $137.42 | +6.99% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is NBIX in an uptrend right now?
NBIX has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is NBIX overbought or oversold?
NBIX's RSI (14) is 60. The stock is in neutral territory, neither overbought nor oversold.
Is NBIX outperforming the market?
NBIX has a Relative Strength (RS) Rating of 41 out of 99. NBIX is currently lagging the broader market.
Where is NBIX in its 52-week range?
NBIX is trading at $147.02, which is 92% of its 52-week high ($160.18) and 70% above its 52-week low ($115.66).
How volatile is NBIX?
NBIX has a Beta of 0.76 and 52-week volatility of 31%. It's less volatile than the S&P 500 - generally more stable.